Novartis Ag & Anr. v. Assistant Controller Of Patents And Designs

When a multinational pharmaceutical company files a patent application, it expects a rigorous but fair examination. But what happens when the patent office says no? For Novartis AG, one of the world's largest pharmaceutical companies, a refusal to grant a patent in India became the catalyst for a legal battle that underscores just how complex and uncertain the patent application process can be—even for industry giants. This case is a reminder that securing intellectual property rights is rarely a straight path, and that even the most established players must fight for their innovations.

Novartis AG and another party (referred to as Anr.) filed an appeal challenging a decision by the Assistant Controller of Patents. The dispute centered on Indian Patent Application No. 10611/DELNP/2015, which had been refused by the patent authority. The refusal by the Assistant Controller prompted the appellants to seek judicial intervention, bringing the matter before the court on 9 August 2021. The case highlights the tension between patent applicants and patent examiners, a friction that plays out regularly in jurisdictions around the world.

The appellants—Novartis AG and an associated party—argued that the Assistant Controller's refusal to grant their patent application was unjustified, and they sought to overturn that decision through an appeal. On the other side stood the Assistant Controller of Patents, defending the original refusal. The core legal friction lay in whether the patent application met the requirements for grant under Indian patent law. The appellants filed an interlocutory application related to document filing, signaling that additional evidence or paperwork was critical to their case. This procedural step suggested that the appellants believed the record needed to be supplemented to properly argue their position before the court.

On 9 August 2021, the court allowed the interlocutory application concerning document filing, permitting the appellants to submit the relevant paperwork. The court also issued notice to the Defendant—the Assistant Controller of Patents—formally bringing the respondent into the proceedings. The matter was then set down for further hearing, meaning the substantive arguments on the patent refusal have yet to be fully adjudicated. As of this stage, the case remains pending, leaving the ultimate fate of Patent Application No. 10611/DELNP/2015 unresolved.

For founders, startup leaders, and IP professionals, this case offers a clear lesson: a patent refusal is not the end of the road, but it is a serious obstacle that demands immediate and strategic action. When a patent office rejects an application, the clock starts ticking on appeal deadlines and procedural requirements. Building a strong record from the outset—meticulous documentation, clear technical disclosures, and well-prepared responses to examiner objections—can make the difference between a successful appeal and a lost innovation. Even global giants like Novartis must navigate these procedural minefields, proving that no company is too big to be caught off guard by a patent refusal.